News Releases

Printer friendly version

Protox Efficacy Data to be Presented at Leading Cancer Research Conference

Thursday, April 14th, 2005 - Vancouver, British Columbia - Protox Therapeutics Inc. ('Protox' or the 'Company') announces that a paper describing the Company's technology, has been selected for presentation at the 96th Meeting of the American Association of Cancer Research (AACR), to be held in Anaheim, California (April 16- 20, 2005). This prestigious annual conference highlighting the latest developments in cancer research is attended by over 25,000 delegates from universities, research institutions and the pharmaceutical industry.

The paper, entitled Tumoricidal effects of a PSA activated pore forming toxin summarizes studies conducted at Johns Hopkins Medicine under the direction of Dr. Sam Denmeade. The data to be presented at the meeting will provide further evidence of the efficacy of Protox Therapeutics' lead product, which is being developed for the treatment of localized prostate cancer.

The paper was co-authored by Dr. Simon Williams, and Dr. Sam Denmeade, both of John Hopkins Medicine and Dr. Tom Buckley, Protox' Chief Scientific Officer. Dr. Williams was awarded the AACR-AFLAC Scholar in Training Award for this research. He will present the paper on Wednesday, April 20.

Protox will issue a release on April 20 outlining some of the information to be presented at the conference.

ABOUT PROTOX: Protox Therapeutics Inc. is developing novel cancer therapeutics by engineering the naturally occurring bacterial toxin Aerolysin, which kills cells by forming pores in them. The Company believes that its engineering approach will produce targeted cancer therapeutics that have greater efficacy and fewer side effects than existing cancer treatments.

For more information, contact:
Terry Vanderkruyk
Director, Investor Relations, Protox Therapeutics Inc.
Tel: 604-688-4376
Cell: 604-789-0844
Fax: 604-688-0173
tvanderkruyk@protoxtherapeutics.com